House lawmakers' latest target in addressing high drug prices: Generic competition

congress
The House Committee on Energy & Commerce Health subcommittee held a hearing to consider measures to address the problem of high prescription drug costs. (Pixabay)

Tactics used by drug companies to delay generic competition are the target of a collection of bills being considered by lawmakers in the latest efforts to address the high price of precision drugs.

“For too long, people have been subjected to the abuse of the patent system by pharmaceutical companies and generic companies entering into agreements and employing tactics that block the competition and keep prices high,” Rep. Anna Eshoo, D-Calif., during a hearing by the House Committee on Energy & Commerce Health subcommittee on Wednesday.

The subcommittee had seven potential measures to consider, including bills aimed at addressing drug company tactics used to restrict access by generic drug makers to their samples or to pay generic competitors with exclusivity to delay the release of a generic competitor.

Conference

2019 Drug Pricing and Reimbursement Stakeholder Summit

Given federal and state pricing requirements arising, press releases from industry leading pharma companies, and the new Drug Transparency Act, it is important to stay ahead of news headlines and anticipated requirements in order to hit company profit targets, maintain value to patients and promote strong, multi-beneficial relationships with manufacturers, providers, payers, and all other stakeholders within the pricing landscape. This conference will provide a platform to encourage a dialogue among such stakeholders in the pricing and reimbursement space so that they can receive a current state of the union regarding regulatory changes while providing actionable insights in anticipation of the future.

They are also eyeing measures to amend the Purple and Orange books used by the Food and Drug Administration to inform manufacturers about active patents.

RELATED: Trump administration proposal would allow Part D plans to negotiate prices of drugs in 'protected' classes

While the different bills up for consideration in committee would employ different tactics, each would be aimed at introducing competition into the market sooner, moving drugs to the market more quickly and lowering costs, Eshoo said.

It’s the latest in growing interest by Congress to address the problem of high prescription drug costs, prioritized by the Trump administration with the release of a prescription drug price blueprint last May. It’s also a shift in focus from efforts which, so far, have largely focused on the lack of price transparency, on the role of payers such as Medicare in negotiating prices, the impact of overseas markets and on hidden financial arrangements involving pharmacy benefit managers.

See the hearing below.

 

Read more on

Suggested Articles

Attorneys general seeking to defend the ACA argue that their opponents—including the DOJ—have poor legal standing to challenge the law.

What are some of the biggest challenges for independent medical practices?

Researchers at two universities plan to develop an autonomous trauma care system that uses robotics and artificial intelligence to treat soldiers.